RxDoctor Payments DataLook up a doctor →

David Cohen, MD

Dermatology · Macon, GANPI 1487652020

Payments from drug & device makers

$5,521,040in general payments, 2019–2025

Across 4,006 payments — averaging $1378.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$814K
  • Amgen$759K
  • Regeneron$703K
  • Eli Lilly$479K
  • Regeneron Healthcare Solutions, Inc.$347K
  • Sanofi US Services Inc.$295K
  • plus $2.1M from 49 others
$18,809in research payments, 2019–2025

Across 18 payments — averaging $1044.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$15K
  • Regeneron$3K

What the payments were for

  • Consulting fees$107,0834%
  • Speaking & faculty fees$2,354,73782%
  • Travel & lodging$326,93711%
  • Food & beverage$78,4483%
  • Education$8840%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)910$813,659
Amgen198$758,518
Regeneron199$702,989
Eli Lilly31$479,207
Regeneron Healthcare Solutions, Inc.371$347,221
Sanofi US Services Inc.26$294,986
Janssen Scientific Affairs, LLC196$293,747
Janssen Research & Development, LLC45$240,425
Johnson & Johnson(2 entities)272$214,396
Sanofi194$213,354
Sun Pharmaceutical Industries Inc.166$176,007
Dermavant Sciences, Inc.192$148,627
Pfizer137$133,395
Lilly USA, LLC199$129,749
UCB, Inc.226$127,213
Incyte Corporation136$113,467
Novartis130$96,842
Galderma Laboratories, L.p.86$46,090
LEO Pharma AS15$44,196
Bristol Myers Squibb40$34,419
Ortho Dermatologics, A Division Of Bausch Health US, LLC49$28,182
Takeda Pharmaceuticals U.S.A., Inc.7$22,618
LEO Pharma Inc.49$18,863
Organon15$9,527
UCB SA3$8,356
Dermira, Inc.8$8,287
Kyowa Kirin, Inc.12$6,373
EPI Health, LLC6$5,738
Revance Therapeutics, Inc.11$1,112
Aclaris Therapeutics, Inc.3$527
Sanofi-aventis U.S. LLC7$454
E.r. Squibb & Sons, L.L.C.6$315
Organogenesis Inc.7$307
Merz North America, Inc.9$307
VYNE Pharmaceuticals Inc.5$272
Arcutis Biotherapeutics, Inc.8$234
Boehringer Ingelheim4$183
Biofrontera Inc.4$183
Kerecis Limited3$174
Helsinn Therapeutics (U.S.), Inc.1$125
Mayne Pharma Commercial LLC3$66
Convatec Inc.1$54
Osiris Therapeutics Inc.1$31
Taro Pharmaceuticals USA, Inc.2$29
Promius Pharma LLC2$25
Genentech USA, Inc.2$24
Paratek Pharmaceuticals, Inc.1$24
Prugen, Inc. Pharmaceuticals1$23
DUSA Pharmaceuticals, Inc.1$23
Sanara Medtech Inc.1$19
Almirall LLC1$19
Fresenius Kabi USA, LLC1$18
Aurinia Pharma U.S., Inc.1$16
Merck1$14
Musculoskeletal Transplant Foundation Inc.1$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,521,040 in reported general payments places this provider in the 95th percentile of 345 dermatology providers in Georgia.

See all dermatology providers in Georgia

Medicare billing

Part B allowed, 2024
$905,003
Medicare patients
1,053
Services billed
8,066

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib60$406,607
Humira(Cf) PenAdalimumab40$378,183
Dupixent PenDupilumab65$263,271
Skyrizi PenRisankizumab-Rzaa12$243,519
TremfyaGuselkumab13$173,914
Dupixent SyringeDupilumab33$122,267
Enbrel SureclickEtanercept17$118,935
Acitretin37$12,634
Clobetasol Propionate97$5,305
Spironolactone78$1,969
ValacyclovirValacyclovir Hcl41$1,644
Hydroxychloroquine Sulfate24$1,520
Fluorouracil25$1,249
Pimozide17$937
Doxycycline Hyclate25$727

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$813,659$406,60760 claims
Johnson & JohnsonTremfya$214,396$173,91413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 345 dermatology providers in Georgia.

Other dermatology in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →